title: The effect of omalizumab on ventilation and perfusion in adults with allergic asthma.
abstract: Omalizumab promotes clinical improvement in patients with allergic asthma, but its effect on pulmonary function is unclear. One possibility is that omalizumab improves asthma symptoms through effects on the regional distributions of ventilation, perfusion, and ventilation/perfusion matching, metrics which can be assessed with Nitrogen-13-saline Position Emission Tomography (PET). Four adults with moderate to severe uncontrolled allergic asthma underwent symptom assessment, spirometry and functional pulmonary imaging with Nitrogen-13-saline PET before and after 4-5 months of treatment with omalizumab. PET imaging was used to determine ventilation/perfusion ratios, the heterogeneity (coefficient of variation, COV) of ventilation and perfusion, and lung regions with ventilation defects. There were no significant changes in spirometry values after omalizumab treatment, but there was a trend towards an improvement in symptom scores. There was little change in the matching of ventilation and perfusion. The COV of perfusion was similar before and after omalizumab treatment. The COV of ventilation was also similar before (0.57 (0.28)) and after (0.66 (0.13)) treatment, and it was similar to previously published values for healthy subjects. There was a non-significant trend towards an increase in the extent of ventilation defects after omalizumab treatment, from 5 (15)% to 12.8 (14.7)%. Treatment of moderate to severe uncontrolled allergic asthma with omalizumab did not result in a significant improvement in ventilation and perfusion metrics assessed with functional PET imaging. The normal COV of ventilation which was unaffected by treatment supports the hypothesis that omalizumab exerts its clinical effect on lung function during allergen exposure rather than in between exacerbations.
authors.affiliation: The Department of Medicine, Pulmonary and Critical Care Unit, Massachusetts General Hospital and Harvard Medical School Boston, MA, USA.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Kelmenson
authors.forename: Vanessa J
authors.initials: VJ
authors.lastname: Kelly
authors.forename: Tilo
authors.initials: T
authors.lastname: Winkler
authors.forename: Mamary T
authors.initials: MT
authors.lastname: Kone
authors.forename: Guido
authors.initials: G
authors.lastname: Musch
authors.forename: Marcos F Vidal
authors.initials: MF
authors.lastname: Melo
authors.forename: Jose G
authors.initials: JG
authors.lastname: Venegas
authors.forename: R Scott
authors.initials: RS
authors.lastname: Harris
keywords: PET functional imaging; V/Q ratios; Xolair; asthma; omalizumab
references.citation: Allergy. 2004 Jul;59(7):701-8
references.pmid: 15180756
references.citation: J Allergy Clin Immunol. 2001 Aug;108(2):184-90
references.pmid: 11496232
references.citation: Allergy. 2005 Mar;60(3):309-16
references.pmid: 15679715
references.citation: Eur Respir J. 2002 Nov;20(5):1088-94
references.pmid: 12449159
references.citation: Respir Med. 2007 Jul;101(7):1483-92
references.pmid: 17339107
references.citation: Am J Respir Crit Care Med. 1999 Jan;159(1):179-87
references.pmid: 9872837
references.citation: J Allergy Clin Immunol. 2009 Dec;124(6):1210-6
references.pmid: 19910033
references.citation: PLoS One. 2012;7(12):e53216
references.pmid: 23285270
references.citation: J Appl Physiol (1985). 2009 Jul;107(1):266-74
references.pmid: 19443742
references.citation: Clin Exp Allergy. 2004 Apr;34(4):632-8
references.pmid: 15080818
references.citation: J Allergy Clin Immunol. 2004 Jan;113(1):59-65
references.pmid: 14713908
references.citation: Thorax. 1992 Feb;47(2):76-83
references.pmid: 1549827
references.citation: Am J Respir Crit Care Med. 2004 Sep 15;170(6):583-93
references.pmid: 15172898
references.citation: J Appl Physiol (1985). 2012 Sep;113(6):947-57
references.pmid: 22678958
references.citation: N Engl J Med. 2006 Jun 22;354(25):2689-95
references.pmid: 16790701
references.citation: Chest. 2006 Jul;130(1 Suppl):4S-12S
references.pmid: 16840363
references.citation: Chest. 2004 Apr;125(4):1378-86
references.pmid: 15078749
references.citation: Am J Physiol. 1984 May;246(5 Pt 2):R665-77
references.pmid: 6720989
references.citation: Am J Respir Crit Care Med. 2006 Aug 1;174(3):245-53
references.pmid: 16690973
references.citation: Ann Allergy Asthma Immunol. 2003 Aug;91(2):154-9
references.pmid: 12952109
references.citation: Eur Respir J. 2001 Aug;18(2):254-61
references.pmid: 11529281
references.citation: Pediatrics. 2001 Aug;108(2):E36
references.pmid: 11483846
references.citation: Nature. 2005 Apr 7;434(7034):777-82
references.pmid: 15772676
references.citation: Am J Respir Crit Care Med. 1997 Jun;155(6):1828-34
references.pmid: 9196082
references.citation: J Appl Physiol (1985). 2007 Jan;102(1):448-58
references.pmid: 17038490
references.citation: N Engl J Med. 2011 Mar 17;364(11):1005-15
references.pmid: 21410369
references.citation: Eur Respir J. 2002 Jul;20(1):73-8
references.pmid: 12166585
references.citation: J Allergy Clin Immunol. 2003 Feb;111(2):278-84
references.pmid: 12589345
references.citation: J Nucl Med. 2003 Dec;44(12):1982-91
references.pmid: 14660725